The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
September 4th 2025
Amaal Starling, MD, FAHS, FAAN, associate professor of neurology at Mayo Clinic College of Medicine, shared data recently presented at AHS 2025 showing that eptinezumab extended the time between migraine attacks.
OnabotulinumtoxinA sBLA Accepted for Detrusor Overactivity Due to Neurologic Conditions
June 29th 2020The sBLA for onabotulinumtoxinA is supported by the findings from a randomized, double-blind phase 3 study evaluating the safety and efficacy of onabotulinumtoxinA in more than 100 pediatric patients.
Migraine Care During a Pandemic: Takeaways for the Future
June 24th 2020In part 2 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, describes the lessons he and his residents have learned during the COVID-19 pandemic and how they'll impact the future of care.
Fred Cohen, MD: Combining CGRPs and OnabotulinumtoxinA for Migraine Prevention
June 22nd 2020The internal medicine resident physician at Montefiore Health System offers insight into the combined use of CGRP medications and Botox to optimize migraine prevention in patients who have inadequate response with Botox alone.
Neurology and COVID-19: Adapting Specialty Care During the Pandemic
June 20th 2020In Part 1 of this interview, Matthew Robbins, MD, director of the Neurology Residency Program at Weill Cornell Medicine, shares his experience caring for headache patients in the epicenter of the coronavirus 2019 pandemic.
Gilbert L'Italien, PhD: The Economic Impact of MIDAS Disability Grades in Migraine
June 20th 2020The senior VP of Global Health Economics and Outcomes Research and Epidemiology at Biohaven Pharmaceuticals discussed the findings from a poster presentation on the economic impact of migraine disability at AHS 2020.
Ubrogepant Effective for Migraine Patients With Insufficient Triptan Response
June 19th 2020The recently approved Allergan agent reported lower rates of functional disability and better overall satisfaction with treatment, as well as similar success for those who did not experience efficacy with triptans.